Max Nisen, Bloomberg Opinion health care columnist, on AbbVie buying Botox maker Allergan for $63 billion. CoinShares Chairman Danny Masters discusses the bitcoin rally and Facebook's new Libra cryptocurrency. Lynn Franco, Senior Director of Economic Indicators and Surveys at The Conference Board, discusses how trade and tariffs worries are draining consumer confidence.  Hal Brands, the Henry A. Kissinger Distinguished Professor at Johns Hopkins University and a Bloomberg Opinion columnist, discusses Trump mulling ending the postwar defense pact with Japan. Hosted by Lisa Abramowicz and Paul Sweeney.

<p>Max Nisen, Bloomberg Opinion health care columnist, on AbbVie buying Botox maker Allergan for $63 billion. CoinShares Chairman Danny Masters discusses the bitcoin rally and Facebook's new Libra cryptocurrency. Lynn Franco, Senior Director of Economic Indicators and Surveys at The Conference Board, discusses how trade and tariffs worries are draining consumer confidence.  Hal Brands, the Henry A. Kissinger Distinguished Professor at Johns Hopkins University and a Bloomberg Opinion columnist, discusses Trump mulling ending the postwar defense pact with Japan. Hosted by Lisa Abramowicz and Paul Sweeney.</p>

Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

<p>Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.</p>

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

Allergan Is A Short-Term Cosmetic Fix For AbbVie: Nisen

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/0a339fb7-5e28-4271-814d-ae3c00542bfc/transcript

Advertisement